| Dr Douglas Michael Adel, DDS | |
|
14211 N.w. 150th Ave, Alachua, FL 32615-2047 | |
| (386) 462-4635 | |
| (386) 462-3009 |
| Full Name | Dr Douglas Michael Adel |
|---|---|
| Gender | Male |
| Speciality | Dentist |
| Location | 14211 N.w. 150th Ave, Alachua, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508969932 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 122300000X | Dentist | DN-11414 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas Michael Adel, DDS 14211 N.w. 150th Ave, P.o. Box 2047, Alachua, FL 32616-2047 Ph: (386) 462-4635 | Dr Douglas Michael Adel, DDS 14211 N.w. 150th Ave, Alachua, FL 32615-2047 Ph: (386) 462-4635 |
News Archive
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, will initiate a comparative pharmacokinetic and bioavailability study of TNX-102, a novel dosage oral formulation of cyclobenzaprine for the treatment of FM, following the U.S. Food and Drug Administration clearance of the Company's initial Investigational New Drug Application.
Pennsylvanians with autism could have broader opportunities to participate in and contribute to their communities if more effort is made to create affordable housing tailored to their needs, a new state report finds.
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.
The final report into Covid-19 disparities sets out how Government research identified the key virus risk factors - such as occupation, household size and wider living circumstances - for specific groups and used that data to provide targeted, evidence-based guidance and advice on how to reduce the risk of infection.
› Verified 5 days ago
Dr. Marc Vincent Cauchon, D.M.D. Dentist Medicare: Not Enrolled in Medicare Practice Location: 14601 N.w. 140 Street, Alachua, FL 32615 Phone: 386-418-3636 Fax: 386-418-3630 | |
Justin Scott Mitchell, Dentist Medicare: Not Enrolled in Medicare Practice Location: 14690 Nw 151st Blvd # 20, Alachua, FL 32615 Phone: 386-462-1771 |